EQS-News: Quo vadis legalisation: SYNBIOTIC and GOC NEXUS at the International Cannabis Business Conference (ICBC) in Berlin

Quo vadis legalisation: SYNBIOTIC and GOC NEXUS at the International Cannabis Business Conference (ICBC) in Berlin

The European industrial hemp and cannabis company group SYNBIOTIC SE (ISIN DE000A3E5A59 | WKN A3E5A5) will be on 29 and 30 April. exhibiting The International Cannabis Business Conference in Berlin is the largest B2B event together with GOC NEXUS at the ICBC in Berlin for political and business leaders in the cannabis industry in Europe.

SYNBIOTIC and GOC NEXUS have had a strategic partnership since December 2024. GOC NEXUS is one of the world's leading providers for the microbiological decontamination of cannabis GACP raw materials into EU GMP medicinal products. The cold plasma disinfection process for cannabis used helps manufacturers of medicinal cannabis to fulfil the extremely high standards of hygiene and quality in an efficient and environmentally friendly manner. Cold plasma effectively kills bacteria, viruses and fungi without the use of chemicals and without damaging the plant structure.

A shift to the right equals a step backwards?

"The results of the 2025 federal election are very likely to have an impact on future cannabis policy in Germany. It is to be feared that the shift to the right will lead to a regression in drug policy," explains Daniel Kruse, CEO of SYNBIOTIC. "But on the other hand, we and renowned experts firmly convinced that medicinal cannabis and THC will continue to be considered medicine and will not be wrongly reclassified and stigmatised as narcotics again."

With several holdings in the medical cannabis sector, SYNBIOTIC is one of the big players in the European medical cannabis market. "This is another reason why it is important for us not to let up with our work and to continue our involvement at the ICBC in Berlin and other professional events“ Kruse explains.

Industrial hemp creates jobs

As an entrepreneur and President of the European Industrial Hemp Association (EIHA) Kruse has also been campaigning for the industrial use of hemp for years. "Politicians must finally address the issue of industrial hemp in an objective and goal-oriented manner and create a fair legal framework, also for Germany in international competition. It is unacceptable that all farmers, producers and traders involved in the industrial hemp value chain are repeatedly subjected to reprisals. If something isn't done about this soon, we can forget about industrial hemp, a potential market worth billions, in Germany. That would be a great pity for the jobs and tax revenues. It would be another missed opportunity for Germany to take an economic, promising and sustainable leading position in Europe. As President of the European Industrial Hemp Association (EIHA), I am delighted with the support of the German Farmers' Association in regard to an EU-wide clarification of the legality of all plant parts of industrial hemp and the definition of marketing standards within the EU."

The German „hemp liberalisation initiative“ also aims to remove the so-called intoxication clause. This clause is considered the biggest obstacle to the industrial use of hemp, as it severely hinders the cultivation and processing of industrial hemp and the sale of products made from it. Deleting this clause would simplify cultivation and utilisation and reduce the bureaucratic burden. The Federal Council had already approved the Industrial Hemp Liberalisation Act presented last year, including the deletion of the intoxication clause. But this was before the federal elections.

The year 2024 was a milestone for the entire German industrial hemp and cannabis industry. The legalisation of cannabis and its removal from the Narcotics Act revolutionised the market in Germany. According to industry reports, the market for medical cannabis in Germany could grow to over one billion euros by 2028 (Source: Franziska Katterbach, Oppenhoff & Partner Rechtsanwälte Steuerberater). "And now Mr Merz and Mr Söder want to reverse all that? This would once again slow down the dynamic, successful development of a world-leading medical cannabis industry. And without this partial legalisation and the liberalisation of industrial hemp, another billion-euro market for the industrial use of hemp as a raw material cannot be developed. The new government should rather be happy about the jobs and tax revenues of both industrial sectors and promote emerging industries in this country instead of hindering them," says SYNBIOTIC CEO Daniel Kruse.

Between October 2025 and March 2028, comprehensive reports will be available on the social impact, in particular on the protection of children and young people, health protection and cannabis-related crime. In addition, an evaluation of the possession quantities and dispensing quantities in the cultivation associations is planned. "The political opponents of cannabis should therefore rely less on their half-knowledge and instead wait for serious data and facts. I believe it also is highly likely that it will be agreed in the coalition negotiations between the CDU/CSU and SPD to wait for the results of the mandatory evaluation before making any further joint decisions on this issue. In view of the many pressing global crises and internal structural problems in Germany, there will hardly be time in the coalition negotiations to argue at length about a cannabis reform." Daniel Kruse continues.

Performance and new dosage form for medicinal cannabis

SYNBIOTIC is in a solid position and, as one of Europe's leading listed corporate groups also has positive news to report: The sales figures for the WEECO Pharma investment are once again above the expected target figures. In addition, SYNBIOTIC will shortly be presenting initial information on the launch of innovative and alternative dosage form for medicinal cannabis that is not yet available on the market.

Publisher
SYNBIOTIC SE
Daniel Kruse
Managing Director
Münsterstrasse 336
40470 Düsseldorf
Germany
www.synbiotic.com

Media contact
Rüdiger Tillmann
SYNBIOTIC Public Relations Manager
e-mail ruediger.tillmann@synbiotic.com
Mobile +49 170 9651451
c/o JOLE.group

About SYNBIOTIC
SYNBIOTIC is a listed group of companies in the hemp and cannabis sector with a buy-and-build investment strategy focussed on Europe. The group covers the entire value chain from cultivation to production and retail - from the field to the shelf. The subsidiaries' core businesses are the research and development, production and commercialisation of hemp, CBD and cannabis products.
SYNBIOTIC pursuing is a clear pan-European strategy of further expanding its business areas in order to cover the relevant growth markets while through diversificationminimising risks and increasing opportunities for investors .